Assignee
ABELZETA INC
US·8 granted patents·7 pending applications·4 citations·filing 2019–2025
Top patents by PatentIndex Score
15 records- 0193US12311022B2Bispecific chimeric antigen receptors targeting CD20 and BCMAABELZETA INC·Filed 2024·Granted May 27, 2025·2 cites·6 claims
- 0292US12458667B2Bispecific chimeric antigen receptors targeting CD20 and BCMAABELZETA INC·Filed 2024·Granted Nov 4, 2025·1 cites·4 claims
- 0390US12448432B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofABELZETA INC·Filed 2022·Granted Oct 21, 2025·1 cites·10 claims
- 0487US2026076995A1Bispecific chimeric antigen receptors targeting cd20 and bcmaABELZETA INC·Filed 2025·Application pending·0 cites
- 0585US2025136707A1Bispecific chimeric antigen receptors targeting cd20 and bcmaABELZETA INC·Filed 2024·Application pending·0 cites
- 0681US12583903B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofABELZETA INC·Filed 2022·Granted Mar 24, 2026·0 cites·10 claims
- 0778US2024309337A1Method for large-scale preparation of purified preparation of recombinant lentiviral vector at gmp gradeABELZETA INC·Filed 2024·Application pending·0 cites
- 0878US2025262243A1Bispecific chimeric antigen receptors targeting cd20 and bcmaABELZETA INC·Filed 2025·Application pending·0 cites
- 0974US12356981B2Cell freezing medium for clinical useABELZETA INC·Filed 2022·Granted Jul 15, 2025·0 cites·17 claims
- 1072US12338494B2Reagent and method for fluorescence quantitative real-time PCR detection of RCLABELZETA INC·Filed 2023·Granted Jun 24, 2025·0 cites·7 claims
- 1166US12577541B2Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP gradeABELZETA INC·Filed 2020·Granted Mar 17, 2026·0 cites·7 claims
- 1265US12018293B2Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP gradeABELZETA INC·Filed 2019·Granted Jun 25, 2024·0 cites·8 claims
- 1362US2026027156A1Bispecific chimeric antigen receptors targeting bcma and cd19ABELZETA INC·Filed 2025·Application pending·0 cites
- 1460US2025144215A1Method for enriching tumor infiltrating lymphocytesABELZETA INC·Filed 2023·Application pending·0 cites
- 1559US2024352417A1Device and method for fully enclosed and fully automatic dispensing of cellsABELZETA INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ABELZETA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →